426
Participants
Start Date
November 8, 2021
Primary Completion Date
February 27, 2022
Study Completion Date
February 27, 2022
Observational
In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
Community and Patient Preference Research Pty Ltd, Sydney
Collaborators (1)
Seqirus
INDUSTRY
Glenmark Pharmaceuticals S.A.
INDUSTRY
Community and Patient Preference Research Pty Ltd
INDUSTRY